EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases

Christoph Lederer, Katharina Mayer, Vivien Somogyi, Katharina Kriegsmann, Mark Kriegsmann, Katharina Buschulte, Markus Polke, Peter Findeisen, Felix Herth, Michael Kreuter

Respiration · 2023

DOI: 10.1159/000531945 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respiration, 2023. Verfasst von Christoph Lederer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik Heidelberg, University Hospital Heidelberg and German Center for Lung Resear…. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

As fibrosing interstitial lung diseases (fILDs) are associated with high mortality, monitoring of disease activity under treatment is highly relevant. Krebs von den Lungen-6 (KL-6) is associated with the presence and severity of different fILDs, mainly in Asian patient populations.

Objectives

Our aim was to evaluate KL-6 as a predictive biomarker in fILDs in Caucasian patients.

Methods

Consecutive patients with fILDs were recruited prospectively and serum concentrations of KL-6 were measured at baseline (BL), after 6 and 12 months (6 Months, 12 Months). Clinical characteristics including pulmonary function tests were assessed at 6-monthly visits and correlated with KL-6 BL levels as well as with KL-6 level changes.

Results

A total of 47 fILD patients were included (mean age: 65 years, 68% male). KL-6 levels at BL were significantly higher in fILD patients than in healthy controls (n = 44, mean age: 45, 23% male) (ILD: 1,757 ± 1960 U/mL vs. control: 265 ± 107 U/mL, p < 0.0001). However, no differences were noted between ILD subgroups. KL-6 decreased significantly under therapy (6M∆BL-KL6: −486 ± 1,505 mean U/mL, p = 0.032; 12M∆BL-KL6: −547 ± 1,782 mean U/mL, p = 0.041) and KL-6 level changes were negatively correlated with changes in pulmonary function parameters (forced vital capacity [FVC]: r = −0.562, p < 0.0001; DLCOSB: r = −0.405, p = 0.013). While neither absolute KL-6 levels at BL nor KL-6 level changes were associated with ILD progression (FVC decline ≥10%, DLCOSB decline ≥15% or death), patients with a stable FVC showed significantly decreasing KL-6 levels (p = 0.022).

Conclusions

A decline of KL-6 under therapy correlated with a clinically relevant stabilization of lung function. Thus, KL-6 might serve as a predictive biomarker, which however must be determined by larger prospective cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialHumansMaleAgedMiddle AgedFemaleProspective StudiesLungVital CapacityMucin-1Biomarkers

Stichwörter der Autor:innen

Interstitial lung diseaseKrebs von den Lungen-6Predictive biomarker

Substanzen

Mucin-1Biomarkers

Autor:innen und Institutionen

  • Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik Heidelberg, University Hospital Heidelberg and German Center for Lung Research (DZL), Heidelberg, Germany, christoph.lederer@web.de.
  • Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik Heidelberg, University Hospital Heidelberg and German Center for Lung Research (DZL), Heidelberg, Germany.
  • Mainz Center for Pulmonary Medicine, Department of Pneumology, Mainz University Medical Center and Department of Pulmonary, Critical Care & Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany.
  • Department of Hematology, Oncology and Rheumatology, University Hospital Heidleberg, Heidelberg, Germany.
  • Department of Pathology, University Hospital Heidelberg, Germany and Pathology Wiesbaden, Wiesbaden, Germany.
  • MVZ Labor Dr. Limbach, Heidelberg, Germany.

Zitieren

APA

Lederer, C., Mayer, K., Somogyi, V., Kriegsmann, K., Kriegsmann, M., Buschulte, K., Polke, M., Findeisen, P., Herth, F., & Kreuter, M. (2023). Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases. Respiration. https://doi.org/10.1159/000531945

Vancouver

Lederer C, Mayer K, Somogyi V, Kriegsmann K, Kriegsmann M, Buschulte K, et al. Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases. Respiration. 2023. doi:10.1159/000531945

BibTeX
@article{Lederer2023,
  author = {Lederer, Christoph and Mayer, Katharina and Somogyi, Vivien and Kriegsmann, Katharina and Kriegsmann, Mark and Buschulte, Katharina and Polke, Markus and Findeisen, Peter and Herth, Felix and Kreuter, Michael},
  title = {Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases},
  journal = {Respiration},
  year = {2023},
  doi = {10.1159/000531945}
}
Kostenlos starten →